Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Anemia
Interventions: Erythropoietin alpha, Placebo; Drug
Lead sponsor: Mathew S. Maurer; Other
Eligibility: 55 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis
Interventions: Tranexamic Acid (TXA), ε-Aminocaproic Acid (EACA); Drug
Lead sponsor: Miller Orthopedic Specialists; Other
Eligibility: 18 Years to 90 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Council Bluffs, Iowa

Conditions: Bipolar Disorder
Interventions: Aspirin, N-acetyl-cysteine (NAC), Sugar Pill; Drug · Dietary Supplement
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Postural Orthostatic Tachycardia Syndrome, Orthostatic Intolerance
Interventions: Droxidopa, Atenolol, Placebos; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Deep Partial or Full Thickness Wounds
Interventions: Fibrin Sealant, ARTISS 4IU/ml VH SD, Staples; Biological · Other
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: Up to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 17
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 14 more

Conditions: Hot Flashes
Interventions: Gabapentin Extended Release tablets, Gabapentin; Drug
Lead sponsor: Depomed; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 8
States / cities: Burbank, California • DeLand, Florida • Port Orange, Florida + 5 more

Conditions: Nicotine Dependence
Interventions: N-acetylcysteine, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Type 2 Diabetes Mellitus
Interventions: thiapalmitate tracer, Saline, Insulin; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 2 Diabetes
Interventions: Nateglinide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 28 participants
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Spinal Cord Injuries
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HIV-associated Enteropathy
Interventions: Serum-derived bovine immunoglobulin protein isolate (SBI), Placebo; Other
Lead sponsor: Entera Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 7 more

Conditions: Myasthenia Gravis
Interventions: Rituximab, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 90 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 26
States / cities: Birmingham, Alabama • Davis, California • Los Angeles, California + 22 more

Conditions: Diabetic Nephropathy
Interventions: Repository Corticotropin Injection, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 10
States / cities: Roseville, California • Cooper City, Florida • Miami Springs, Florida + 7 more

Conditions: Asthma
Interventions: ASMA; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 13 Years and older
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Parkinson Disease, Depression
Interventions: OnabotulinumtoxinA, Control; Biological
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hemodialysis, Hypertension, Left Ventricular Hypertrophy
Interventions: Lisinopril, Atenolol; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Orthopaedic Fractures
Interventions: NSAID, Gabapentinoids, placebo; Drug
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 17
States / cities: Miami, Florida • West Palm Beach, Florida • Indianapolis, Indiana + 13 more

Conditions: Prostate Cancer
Interventions: eflornithine, Placebo; Drug
Lead sponsor: Thomas E. Ahlering; Other
Eligibility: 35 Years to 70 Years · Male only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2012
U.S. locations: 1
States / cities: Orange, California

Conditions: Major Depressive Disorder
Interventions: 80 Milligrams NSI-189, Placebo, 40 Milligrams NSI-189; Drug
Lead sponsor: Neuralstem Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 13
States / cities: Garden Grove, California • National City, California • Denver, Colorado + 10 more

Conditions: Myotonic Dystrophy Type 1
Interventions: rhIGF-I/rhIGFBP-3, placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 12
States / cities: Orange, California • Sacramento, California • Kansas City, Kansas + 9 more

Conditions: Fragile X Syndrome
Interventions: placebo, oxytocin 24IU, oxytocin 48IU; Drug
Lead sponsor: Stanford University; Other
Eligibility: 13 Years to 29 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Alzheimer's Disease
Interventions: Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 32
States / cities: Tucson, Arizona • Laguna Hills, California • Lomita, California + 28 more

Conditions: Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With, Glucocorticoid-induced Osteoporosis
Interventions: Denosumab, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 6
States / cities: Los Angeles, California • Wilmington, Delaware • Indianapolis, Indiana + 3 more

Conditions: SARS-CoV-2 Infection, COVID-19
Interventions: BNT162b1, BNT162b2, Placebo, BNT162b2SA; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 12 Years and older
Enrollment: 46,969 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 154
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 106 more

Search by objective public record fields.

Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)

Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement

N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder

Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist

Safety and Efficacy Study of FS 4 IU VH S/D (Fibrin Sealant With 4IU/mL Thrombin, Vapor Heated, Solvent/Detergent Treated) to Adhere Split Thickness Skin Grafts and Improve Wound Healing in Burn Patients

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

N-Acetylcysteine and Smoking Reduction

A Novel Positron Emission Tomography (PET) Approach to Measuring Myocardial Metabolism

Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone

Feasibility of Early Gabapentin as an Intervention for Neurorecovery

Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy

BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis

Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients

Rural Asthma Effectiveness Study

Trial of OnabotulinumtoxinA for Depression in Parkinson Disease

Hypertension in Hemodialysis Patients (Aim 3)

Improving Pain Management and Long Term Outcomes Following High Energy Orthopedic Trauma (Pain Study)

Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer

Study of NSI-189 for Major Depressive Disorder

Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome

Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease

Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals